BWL
UNCY icon

Bogart Wealth LLC’s Unicycive Therapeutics UNCY Stock Holding History

Bogart Wealth LLC’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28 Hold
6
– – ﹤0.01% 1978
2026
Q1 		$39 Hold
6
– – ﹤0.01% 1779
2025
Q4 		$35 Hold
6
– – ﹤0.01% 1571
2025
Q3 		$26 Hold
6
– – ﹤0.01% 1521
2025
Q2 		$29 Hold
6
– – ﹤0.01% 1440
2025
Q1 		$34 Hold
6
– – ﹤0.01% 1391
2024
Q4 		$48 Buy
+6
New +$33 ﹤0.01% 1332

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Bogart Wealth LLC's UNCY Position: Q2 2026 in Review

Bogart Wealth LLC held its Unicycive Therapeutics (UNCY) position steady in Q2 2026 at 6 shares worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #1978.

Bogart Wealth LLC first reported a position in UNCY in Q4 2024 and has held it in 7 quarters since. The position peaked at $48 in Q4 2024. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Bogart Wealth LLC held 6 shares of Unicycive Therapeutics worth $28 as of Q2 2026.
  • Bogart Wealth LLC left its Unicycive Therapeutics share count unchanged in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Bogart Wealth LLC's portfolio in Q2 2026, its #1978 holding.
  • Bogart Wealth LLC first reported a position in Unicycive Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Bogart Wealth LLC's Unicycive Therapeutics position peaked at $48 in Q4 2024.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Bogart Wealth LLC's 13F filing for Q2 2026, filed 24 Jul 2026.